28.43
2.45%
0.68
After Hours:
28.43
Spyre Therapeutics Inc Stock (SYRE) Latest News
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire
SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect - AccessWire
Spyre Therapeutics’ $200 Million Common Stock Offering - Global Legal Chronicle
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics to Present at Evercore ISI HealthCONx Conference | IBD Treatment Updates | SYRE Stock News - StockTitan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect - AccessWire
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation - AccessWire
First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire
Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat
Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN
Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire
Spyre Therapeutics revises net loss per share calculations - Investing.com
Spyre Therapeutics launches $200 million public offering - Investing.com
Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan
Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat
Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com
SYRE Crosses Below Key Moving Average Level - Nasdaq
Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com
Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com
Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat
Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia
FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com
Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World
Spyre reports promising Phase 1 results for IBD therapy - Investing.com India
Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World
Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan
Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat
Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK
Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com
Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World
Spyre Therapeutics director sells shares worth $10,929 - Investing.com India
Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):